EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Enhancing specific thymic Treg activation and function with 4-1BB monomeric streptavidin-based CARs

Jorge Gallego-Valle, Verónica Astrid Pérez-Fernández, Ana Pita, Jesús Rosales-Magallares, Rocío López-Esteban, Sergio Gil-Manso, Diego Carbonell, Ramón Pérez-Caballero, Carlos Pardo, Juan-Miguel Gil-Jaurena, Rafael Correa-Rocha, Marjorie Pion

Translational Research · 2025

DOI: 10.1016/j.trsl.2025.09.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Research, 2025. Verfasst von Jorge Gallego-Valle und 11 weiteren Autor:innen. Beteiligte Einrichtung: Group of Advanced Immune-Regulation (GIRA), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain; Autoimmunity Group, Centre Esther Kopl…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Streptavidin, Receptors, Chimeric Antigen, Thymus Gland. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Instituto de Investigación Sanitaria Gregorio Marañón, Community of Madrid, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyperinflammatory diseases arise from excessive immune activation, causing tissue damage and systemic inflammation. Regulatory T (Treg) cells play a key role in maintaining immune homeostasis, but their function or numbers may be impaired in pathological conditions. Conventional immunosuppressive therapies often fail to restore immune balance and are associated with significant adverse effects. An emerging therapeutic strategy involves the use of chimeric antigen receptor (CAR)-engineered Tregs to suppress aberrant immune responses. However, antigen-specific CAR-Tregs may be insufficient due to the heterogeneity of inflammatory diseases. Universal CAR-Tregs (UniCAR-Tregs), which may recognize broad immune markers, represent a more flexible and potentially effective alternative. In this study, second- and third-generation UniCAR constructs containing a monomeric streptavidin extracellular domain were introduced into human thymus-derived Tregs (thyTregs) via lentiviral transduction. The phenotype and transcriptomic profile of engineered thyTregs were characterized and compared to unmodified controls. Their suppressive capacity was assessed in vitro using a mixed lymphocyte reaction with a biotinylated intermediary, followed by evaluation in a preclinical graft-versus-host disease (GvHD) mouse model. CARs incorporating CD28 co-stimulation resulted in non-specific activation or failed to enhance suppression. In contrast, the UniCAR41BB construct more specifically activated thyTregs and augmented their suppressive function. In vivo, UniCAR41BB thyTregs delayed GvHD onset and improved survival. This study demonstrates, for the first time, that thyTregs can be effectively transduced without compromising their regulatory phenotype. Furthermore, second-generation UniCAR41BB construct enhances antigen-dependent suppressive function, highlighting its potential as a versatile therapeutic platform for GvHD and other inflammatory disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryStreptavidinReceptors, Chimeric AntigenThymus GlandTumor Necrosis Factor Receptor Superfamily, Member 9Lymphocyte ActivationAnimalsHumansMiceGraft vs Host Disease

Stichwörter der Autor:innen

Chimeric antigen receptorEngineered cellsGraft-versus-host diseaseImmunosuppressionStreptavidin-based CARThymus-derived treg

Substanzen

StreptavidinReceptors, Chimeric AntigenTumor Necrosis Factor Receptor Superfamily, Member 9

Autor:innen und Institutionen

  • Group of Advanced Immune-Regulation (GIRA), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain; Autoimmunity Group, Centre Esther Koplowitz (CEK), Fundació Clínic Per a La Recerca Biomèdica, Barcelona, Sp…
  • Group of Advanced Immune-Regulation (GIRA), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain.
  • Paediatric Cardiac Surgery Unit of Gregorio Marañón University Hospital (HGUGM), Madrid, Spain.
  • Laboratory of Immune-regulation (LIR), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain.
  • Laboratory of Immune-regulation (LIR), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain; Columbia Center for Translational Immunology, Columbia University, New York, NY, USA.
  • Group of Advanced Immune-Regulation (GIRA), Gregorio Marañón Health Research Institute (IiSGM), Madrid, Spain. Electronic address: marjorie.pion@iisgm.com.

Förderung

  • Instituto de Investigación Sanitaria Gregorio Marañón
  • Community of Madrid
  • European Regional Development Fund
  • Carlos III Health Institute
  • European Commission
  • Hospital General Universitario Gregorio Marañón

Zitieren

APA

Gallego-Valle, J., Pérez-Fernández, V. A., Pita, A., Rosales-Magallares, J., López-Esteban, R., Gil-Manso, S., Carbonell, D., Pérez-Caballero, R., Pardo, C., Gil-Jaurena, J. M., Correa-Rocha, R., & Pion, M. (2025). Enhancing specific thymic Treg activation and function with 4-1BB monomeric streptavidin-based CARs. Translational Research. https://doi.org/10.1016/j.trsl.2025.09.004

Vancouver

Gallego-Valle J, Pérez-Fernández VA, Pita A, Rosales-Magallares J, López-Esteban R, Gil-Manso S, et al. Enhancing specific thymic Treg activation and function with 4-1BB monomeric streptavidin-based CARs. Translational Research. 2025. doi:10.1016/j.trsl.2025.09.004

BibTeX
@article{GallegoValle2025,
  author = {Gallego-Valle, Jorge and Pérez-Fernández, Verónica Astrid and Pita, Ana and Rosales-Magallares, Jesús and López-Esteban, Rocío and Gil-Manso, Sergio and Carbonell, Diego and Pérez-Caballero, Ramón and Pardo, Carlos and Gil-Jaurena, Juan-Miguel and Correa-Rocha, Rafael and Pion, Marjorie},
  title = {Enhancing specific thymic Treg activation and function with 4-1BB monomeric streptavidin-based CARs},
  journal = {Translational Research},
  year = {2025},
  doi = {10.1016/j.trsl.2025.09.004}
}
Kostenlos starten →